secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-08-27T23:59:59+00:00
Accession:  0001193125-24-207466
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd's pemivibart shows 84% relative risk reduction in symptomatic COVID-19 in Phase 3 exploratory analysis
--------------------------------------------------------------------------------

- 84% relative risk reduction vs placebo (1.9% vs 11.9% symptomatic COVID-19 rate, p=0.000061) over 180 days in immunocompetent cohort.
- Immunocompromised cohort: 3% symptomatic COVID-19 rate; no COVID-19 hospitalizations or deaths over 180 days.
- Safety: anaphylaxis in 0.6% of immunocompromised cohort (2 life-threatening); infusion reactions generally mild-moderate.
- FDA updated PEMGARDA Fact Sheet for Healthcare Providers to include 180-day exploratory efficacy data.
- Data collected during XBB/JN.1 variant waves; company to host conference call at 8:30AM EDT today.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524207466/0001193125-24-207466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524207466/d890200d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-207466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer